Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Src homology 2 domain-containing protein tyrosine phosphatase (SHP2) has emerged as a breakthrough antitumor therapeutic target. Inhibitors targeting SHP2 active site or allosteric site confer new treatments for tumor and inflammatory diseases.